U.S. Court Dismisses Teva’s Patent Infringement Plea Against Dr Reddy’s Carvedilol; Dr Reddy’s May Launch Drug Soon
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Dr Reddy's Labs may be able to sell generic versions of GlaxoSmithKline's hypertension drug Coreg (carvedilol) in the U.S. after it settled a case against Israeli drug maker Teva for four patents of the drug
You may also be interested in...
India Firm Zydus Cadila Takes Teva To U.S. Court Over Risperidone APIs
Indian drug maker’s case argues Teva is interfering with its present and future business.
India Firm Zydus Cadila Takes Teva To U.S. Court Over Risperidone APIs
Indian drug maker’s case argues Teva is interfering with its present and future business.
Zydus Cadila Takes Teva To Virginia Court Asserting Rights Over Risperidone APIs
MUMBAI - As the battle for six-month exclusivity on blockbuster drugs going off-patent intensifies in the U.S., generic companies are opening up a new war front - the quest for patent rights over bulk drugs or active ingredients that go into manufacturing multi-billion dollar drugs